Independent calculation‐based verification of volumetric‐modulated arc therapy?stereotactic body radiotherapy plans for lung cancer
Independent calculation‐based verification of volumetric‐modulated arc therapy?stereotactic body radiotherapy plans for lung cancer
复制标题
基于独立计算的肺癌容积调制弧形放射治疗立体定向放疗方案验证
DOI：
10.1002/acm2.12900
复制
发表时间：
2020
影响因子：
2.1
通讯作者：
Mizowaki Takashi
中科院分区：
文献类型：
--
作者：
Ono Tomohiro;Mitsuyoshi Takamasa;Shintani Takashi;Tsuruta Yusuke;Iramina Hiraku;Hirashima Hideaki;Miyabe Yuki;Nakamura Mitsuhiro;Matsuo Yukinori;Mizowaki Takashi
本研究旨在研究使用二级治疗计划系统（sTPS）对肺癌患者进行体积调制式弧形治疗（VMAT）-立体定向体部放疗（SBRT）的独立计算验证的可行性。本研究共纳入了50例在2018年4月至2019年5月期间接受VMAT‐SBRT的肺癌患者。使用RayStation中的Collapsed-Cone Convolution设计VMAT-SBRT计划（主要TPS：pTPS）。将DICOM文件传输至Eclipse软件（sTPS），该软件使用Eclipse软件，然后使用Acuros XB重新计算剂量分布。为了验证均匀体模中的剂量分布，使用剂量差5%（DD 5%）和伽马指数3%/2 mm（γ3%/2 mm）的通过率评价了pTPS、sTPS和测量值之间的差异。使用ArcCHECK圆柱形二极管阵列进行测量。为了根据患者几何形状独立验证剂量体积参数，对计划靶体积（PTV）的剂量体积指数（包括D95%和等中心剂量）进行了评价。然后计算pTPS和sTPS之间的平均差（±标准差）。DD5%和γ3%/2 mm标准的伽马通过率分别为：pTPS与sTPS的99.2 ± 2.4%和98.6 ± 3.2%，pTPS与测量值的92.9 ± 4.0%和94.1 ± 3.3%，sTPS与测量值的93.0 ± 4.4%和94.3 ± 4.1%。对于D95%的PTV和等中心剂量，pTPS和sTPS之间的差异分别为−3.1 ± 2.0%和−2.3 ± 1.8%。我们对肺癌VMAT‐SBRT计划的调查显示，基于计算的独立验证是一种针对患者特定质量保证的高效方法。
This study aimed to investigate the feasibility of independent calculation‐based verification of volumetric‐modulated arc therapy (VMAT)–stereotactic body radiotherapy (SBRT) for patients with lung cancer using a secondary treatment planning system (sTPS). In all, 50 patients with lung cancer who underwent VMAT‐SBRT between April 2018 and May 2019 were included in this study. VMAT‐SBRT plans were devised using the Collapsed‐Cone Convolution in RayStation (primary TPS: pTPS). DICOM files were transferred to Eclipse software (sTPS), which utilized the Eclipse software, and the dose distribution was then recalculated using Acuros XB. For the verification of dose distribution in homogeneous phantoms, the differences among pTPS, sTPS, and measurements were evaluated using passing rates of a dose difference of 5% (DD5%) and gamma index of 3%/2 mm (γ3%/2 mm). The ArcCHECK cylindrical diode array was used for measurements. For independent verification of dose‐volume parameters per the patient’s geometry, dose‐volume indices for the planning target volume (PTV) including D95%and the isocenter dose were evaluated. The mean differences (± standard deviations) between the pTPS and sTPS were then calculated. The gamma passing rates of DD5% and γ3%/2 mm criteria were 99.2 ± 2.4% and 98.6 ± 3.2% for pTPS vs. sTPS, 92.9 ± 4.0% and 94.1 ± 3.3% for pTPS vs. measurement, and 93.0 ± 4.4% and 94.3 ± 4.1% for sTPS vs. measurement, respectively. The differences between pTPS and sTPS for the PTVs of D95%and the isocenter dose were −3.1 ± 2.0% and −2.3 ± 1.8%, respectively. Our investigation of VMAT‐SBRT plans for lung cancer revealed that independent calculation‐based verification is a time‐efficient method for patient‐specific quality assurance.